Compared to continued use of GLP-1s for three years, which corresponded to an 18% risk reduction, GLP-1 users who experienced interruption and subsequently resumed gained a 12% risk reduction on average
It increases insulin secretion from pancreatic -cells, reduces glucose-adjusted glucagon secretion, and improves insulin sensitivity more than what can be typically achieved through weight loss
Cold Spring Harbor perspectives in biology , 8 (8), a005926
GLP-3 RT is used in preclinical research on triple-agonist incretin pharmacology, energy expenditure and thermogenesis, hepatic lipid metabolism, body composition partitioning, and glucose homeostasis
Meet BPC-157, a peptide that's drawing interest from people looking to support their everyday wellness routines